Want to see ENLV full AI Analyst Report?
ENLV Stock Chart & Stats
$0.86
-$0.07(-5.60%)
At close: 4:00 PM EST
$0.86
-$0.07(-5.60%)
Day’s Range― - ―
52-Week Range$0.52 - $2.10
Previous CloseN/A
Volume59.48K
Average Volume (3M)182.02K
Market Cap
$127.18M
Enterprise Value$13.65M
Total Cash (Recent Filing)$5.87M
Total Debt (Recent Filing)$641.00K
Price to Earnings (P/E)<0.1
Beta0.61
Next Earnings
Apr 23, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)27.02
Shares Outstanding241,048,720
10 Day Avg. Volume216,695
30 Day Avg. Volume182,016
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.02
Price to Sales (P/S)0.00
P/FCF Ratio-3.07
Enterprise Value/Market Cap0.11
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-41.12
Enterprise Value/Ebitda-0.95
Forecast
1Y Price Target
$20.00Price Target Upside2225.58% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.08
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low LeverageVery low debt reduces financial risk and gives management flexibility to fund clinical programs or weather further cash burn without high interest burdens. Over 2–6 months this preserves optionality for non-dilutive financing and limits solvency risk while trials progress.
Advancing Phase 2b ProgramInitiating a statistically powered global Phase 2b with U.S., Danish and Polish sites materially de-risks Allocetra over time. Robust data could validate a large, underserved osteoarthritis market, improving long‑term commercial potential and strategic positioning.
Substantial Digital TreasuryA sizable token treasury provides a structural non‑operating asset cushion that can support R&D funding or strategic initiatives. As a deliberate hybrid strategy, it changes the company’s capital structure and may provide liquidity or funding optionality over months.
Bears Say
Persistent Cash BurnSustained operating losses and negative cash flow indicate dependence on external financing to fund trials. Over the next several months this raises dilution and financing risk, constraining runway until operating cash flow or non‑dilutive funding materializes.
Balance Sheet VolatilityA dramatic one‑year equity swing suggests non‑operating items (token mark‑to‑market or accounting events), reducing reliability of reported stability. This makes forecasting financing needs and asset quality harder across the medium term.
Nasdaq Compliance RiskA potential listing deficiency is a structural governance/liquidity risk: management may need corrective actions (reverse split or other), which can deter institutional holders, complicate capital raises and limit investor access over the coming months.
Enlivex News
ENLV FAQ
What was Enlivex Therapeutics Ltd’s price range in the past 12 months?
Enlivex Therapeutics Ltd lowest stock price was $0.52 and its highest was $2.10 in the past 12 months.
What is Enlivex Therapeutics Ltd’s market cap?
Enlivex Therapeutics Ltd’s market cap is $127.18M.
When is Enlivex Therapeutics Ltd’s upcoming earnings report date?
Enlivex Therapeutics Ltd’s upcoming earnings report date is Apr 23, 2027 which is in 292 days.
How were Enlivex Therapeutics Ltd’s earnings last quarter?
Enlivex Therapeutics Ltd released its earnings results on May 22, 2026. The company reported -$0.02 earnings per share for the quarter, the consensus estimate of -$0.02 by $0.
Is Enlivex Therapeutics Ltd overvalued?
According to Wall Street analysts Enlivex Therapeutics Ltd’s price is currently Undervalued.
Does Enlivex Therapeutics Ltd pay dividends?
Enlivex Therapeutics Ltd does not currently pay dividends.
What is Enlivex Therapeutics Ltd’s EPS estimate?
Enlivex Therapeutics Ltd’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Enlivex Therapeutics Ltd have?
Enlivex Therapeutics Ltd has 241,048,720 shares outstanding.
What happened to Enlivex Therapeutics Ltd’s price movement after its last earnings report?
Enlivex Therapeutics Ltd reported an EPS of -$0.02 in its last earnings report, expectations of -$0.02. Following the earnings report the stock price went down -0.417%.
Which hedge fund is a major shareholder of Enlivex Therapeutics Ltd?
Currently, no hedge funds are holding shares in ENLV
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Enlivex Stock Smart Score
Company Description
Enlivex Therapeutics Ltd
Enlivex Therapeutics Ltd., established in 2005 and based in Nes Ziona, Israel, operates as a clinical-stage biotechnology firm dedicated to macrophage reprogramming immunotherapy. The company is currently advancing Allocetra, its flagship cell-based therapeutic. This treatment is undergoing Phase II clinical evaluation for its effectiveness in addressing organ dysfunction and failure that arises from sepsis. Additionally, Allocetra is being investigated in preclinical studies for its potential application in solid tumor therapy.
ENLV Earnings Call
Q4 2026
0:00 / 0:00
ENLV Stock 12 Month Forecast
Average Price Target
$20.00
▲(2225.58% Upside)
Technical Analysis
Ownership Overview
―
Insiders
0.01% Mutual Funds
0.98% Other Institutional Investors
98.02% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---